DSpace Repository

Switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: changes in bone turnover markers and circulating sclerostin levels

Show simple item record

dc.contributor Universitat de Vic. Càtedra de la Sida i Malalties Relacionades
dc.contributor.author Negredo, Eugenia
dc.contributor.author Diez-Pérez, Adolfo
dc.contributor.author Bonjoch, Anna
dc.contributor.author Domingo, Pere
dc.contributor.author Pérez Alvarez, Núria
dc.contributor.author Gutierrez, Mar
dc.contributor.author Mateo, Gracia
dc.contributor.author Puig, Jordi
dc.contributor.author Echeverria, Patricia
dc.contributor.author Escrig, R.
dc.contributor.author Clotet, Bonaventura
dc.date.accessioned 2015-09-18T11:49:00Z
dc.date.available 2015-09-18T11:49:00Z
dc.date.created 2015
dc.date.issued 2015
dc.identifier.citation Negredo, E., Diez-Pérez, A., Bonjoch, A., Domingo, P., Pérez-Álvarez, N., Gutierrez, M., et al. (2015). Switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: Changes in bone turnover markers and circulating sclerostin levels. Journal of Antimicrobial Chemotherapy, 70(7), 2104-2107. ca_ES
dc.identifier.issn 0305-7453
dc.identifier.issn 1460-2091
dc.identifier.uri http://hdl.handle.net/10854/4184
dc.description.abstract Background: Tenofovir is involved in accelerated bone mineral density (BMD) loss. Methods: We recently published a hip BMD improvement at week 48 [+2.1% (95% CI: 20.6, 4.7) (P¼0.043)] in HIV-infected patients with osteopenia/osteoporosis randomized to switch from tenofovir to abacavir (n¼26), although without reaching statistical significance compared with those who maintained tenofovir (n¼28). Here, we present changes at week 48 in bone markers [C-terminal telopeptide of collagen type 1 (CTX), osteocalcin and procollagen type 1 N propeptide (P1NP)] as well as in circulating levels of three proteins involved in bone regulation [osteoprotegerin, receptor activator for NF-kB ligand (RANKL) and sclerostin, a selective regulator of bone formation through the Wnt pathway] in 44 of these patients. x2 or Fisher and Student t-tests were performed according to the distribution of the variables. Results: Bone markers decreased only in the abacavir group [mean (SD) CTX changed from 0.543 (0.495) to 0.301 (0.306) ng/mL; mean (SD) osteocalcin changed from 23.72 (22.20) to 13.95 (12.40) ng/mL; and mean (SD) P1NP changed from 54.68 (54.52) to 28.65 (27.48) ng/mL (P,0.001 in all cases)], reaching statistical significance between the groups at week 48. Osteoprotegerin did not vary, but sclerostin significantly increased in the abacavir group [from 29.53 (27.91) to 35.56 (34.59) pmol/L, P¼0.002]. No significant differences in osteoprotegerin and sclerostin were detected between the groups at week 48. RANKL values were below the limit of detection in all samples. Conclusions: The switch from tenofovir to abacavir seems to induce a positive effect on bone tissue, since bone turnover markers decreased. In addition, circulating sclerostin levels increased, a change associated with improved bone properties. en
dc.format application/pdf
dc.format.extent 4 p.
dc.language.iso eng
dc.publisher Oxford University Press ca_ES
dc.rights Tots els drets reservats ca_ES
dc.rights (c) Oxford University Press
dc.subject.other Sida -- Tractament ca_ES
dc.title Switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: changes in bone turnover markers and circulating sclerostin levels en
dc.type info:eu-repo/semantics/article ca_ES
dc.identifier.doi https://doi.org/10.1093/jac/dkv063
dc.rights.accessRights info:eu-repo/semantics/closedAccess ca_ES
dc.type.version info:eu-repo/publishedVersion ca_ES
dc.indexacio Indexat a WOS/JCR ca_ES
dc.indexacio Indexat a SCOPUS ca_ES

Files in this item

Show simple item record

Search RIUVic


Advanced Search

Browse

Statistics